LEO 15520

Drug Profile

LEO 15520

Alternative Names: Inflammation therapy - LEO Pharma; Inflammatory disorders therapy - LEO Pharma; LEO-15520

Latest Information Update: 08 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 08 Apr 2008 Discontinued - Phase-I for Inflammation in Denmark (PO)
  • 09 Nov 2006 Phase-I clinical trials in Inflammation in Denmark (PO)
  • 26 Sep 2005 Preclinical trials in Inflammation in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top